Kawasumi Laboratories Inc. reported consolidated earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net sales of ¥6,226 million against ¥6,048 million a year ago. Operating income was ¥179 million against ¥309 million a year ago. Ordinary income was ¥251 million against ¥173 million a year ago. Profit attributable to owners of the parent was ¥190 million or ¥8.73 per share against ¥393 million or ¥18.03 per share a year ago. Profit before income taxes was ¥251 million against ¥170 million a year ago. Net cash provided by operating activities was ¥515 million against ¥778 million a year ago. Purchase of property, plant and equipment was ¥216 million against ¥616 million a year ago. Purchase of intangible assets was ¥32 million against ¥49 million a year ago.

For the six months ending September 30, 2017, the company expects net sales of ¥12,300 million, operating income of ¥100 million, ordinary income of ¥150 million and profit attributable to owners of the parent of ¥150 million or ¥6.88 per share.

For the full year ending March 31, 2018, the company expects net sales of ¥25,000 million, operating income of ¥600 million, ordinary income of ¥650 million and profit attributable to owners of the parent of ¥600 million or ¥27.50 per share.

For the fiscal year ending March 31, 2018, the company expects to pay second quarter-end dividend of JPY 7.50 per share against JPY 7.50 per share paid a year ago.

For the fiscal year ending March 31, 2018, the company expects to pay year-end dividend of JPY 7.50 per share against JPY 10.00 per share paid a year ago.